|
G |
A2ml1 |
alpha-2-macroglobulin-like 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of OVOS2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:161,815,111...161,857,286
Ensembl chr 4:161,814,708...161,857,343
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ABAT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA panobinostat results in decreased expression of ABCA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd14a |
abhydrolase domain containing 14A |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ABHD14A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:107,079,139...107,089,004
Ensembl chr 8:107,079,144...107,086,985
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acad11 |
acyl-CoA dehydrogenase family, member 11 |
increases expression |
ISO |
panobinostat results in increased expression of ACAD11 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ACKR3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression multiple interactions |
ISO |
Panobinostat results in increased expression of ACP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA panobinostat results in increased expression of ACSL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
increases expression |
ISO |
panobinostat results in increased expression of ACSM3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Panobinostat results in decreased expression of ACTA2 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ada |
adenosine deaminase |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA panobinostat results in decreased expression of ADA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ADAM12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA panobinostat results in decreased expression of ADAM22 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA panobinostat results in increased expression of ADAM28 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:43,774,463...43,840,726
Ensembl chr15:42,944,467...43,840,672
|
|
G |
Adamts15 |
ADAM metallopeptidase with thrombospondin type 1 motif, 15 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA panobinostat results in increased expression of ADAMTS15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
|
|
G |
Adamts17 |
ADAM metallopeptidase with thrombospondin type 1 motif, 17 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:120,445,800...120,768,204
Ensembl chr 1:120,445,749...120,768,202
|
|
G |
Adamts19 |
ADAM metallopeptidase with thrombospondin type 1 motif, 19 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA panobinostat results in increased expression of ADAMTS19 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:52,346,448...52,531,245
Ensembl chr18:52,347,428...52,530,509
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ADCYAP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA panobinostat results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA panobinostat results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
|
|
G |
Adgrl3 |
adhesion G protein-coupled receptor L3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ADGRL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860
|
|
G |
Adgrv1 |
adhesion G protein-coupled receptor V1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA panobinostat results in decreased expression of ADGRV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:11,331,434...11,911,713
Ensembl chr 2:11,331,442...11,911,688
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Afap1l1 |
actin filament associated protein 1-like 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AFAP1L1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:55,183,786...55,244,174
Ensembl chr18:55,183,786...55,244,146
|
|
G |
Ahnak |
AHNAK nucleoprotein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AHNAK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ajap1 |
adherens junctions associated protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA panobinostat results in increased expression of AJAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:163,907,846...164,021,004
Ensembl chr 5:163,907,847...164,020,317
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA panobinostat results in decreased expression of AKAP12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein |
CTD |
PMID:18445700 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALCAM mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ALDH1A2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALDH1A3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALDH1L2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Alkal2 |
ALK and LTK ligand 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA panobinostat results in increased expression of ALKAL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:47,495,645...47,505,235
Ensembl chr 6:47,495,782...47,505,234
|
|
G |
Alx1 |
ALX homeobox 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ALX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:38,157,626...38,177,220
Ensembl chr 7:38,147,117...38,177,220
|
|
G |
Amer2 |
APC membrane recruitment protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of AMER2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA panobinostat results in increased expression of AMIGO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Ang |
angiogenin |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:24,312,711...24,323,361
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA panobinostat results in increased expression of ANGPT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA panobinostat results in increased expression of ANGPT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Ankh |
ANKH inorganic pyrophosphate transport regulator |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA panobinostat results in increased expression of ANKH mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA panobinostat results in increased expression of ANKRD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Ano3 |
anoctamin 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
panobinostat results in increased expression of ANXA1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa2 |
annexin A2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ANXA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa3 |
annexin A3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA panobinostat results in increased expression of ANXA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa9 |
annexin A9 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374
|
|
G |
Aox1 |
aldehyde oxidase 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of AOX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1m2 |
adaptor related protein complex 1 subunit mu 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA panobinostat results in increased expression of AP1M2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:19,838,579...19,856,560
Ensembl chr 8:19,838,580...19,856,482
|
|
G |
Ap5s1 |
adaptor related protein complex 5 subunit sigma 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of AP5S1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:118,429,618...118,432,929
Ensembl chr 3:118,429,637...118,432,926
|
|
G |
Apela |
apelin receptor early endogenous ligand |
increases expression |
ISO |
Panobinostat results in increased expression of APELA mRNA |
CTD |
PMID:26272509 |
|
NCBI chr16:24,694,356...24,703,466
Ensembl chr16:24,694,324...24,703,465
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARAP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:46,717,657...46,917,326
Ensembl chr14:46,718,760...46,917,154
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA panobinostat results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA panobinostat results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA panobinostat results in increased expression of ARHGAP18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARHGAP5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arhgap6 |
Rho GTPase activating protein 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARHGAP6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:24,953,464...25,490,003
Ensembl chr X:24,953,464...25,488,663
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
affects expression multiple interactions |
ISO |
panobinostat affects the expression of ARID2 mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA panobinostat results in increased expression of ARID5B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Armh4 |
armadillo-like helical domain containing 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA panobinostat results in decreased expression of ARMH4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ARRB1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arx |
aristaless related homeobox |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ARX mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872
|
|
G |
Asb9 |
ankyrin repeat and SOCS box-containing 9 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:29,956,576...30,001,436
Ensembl chr X:29,956,576...30,001,105
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASNS mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Astn1 |
astrotactin 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ASTN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ASTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
panobinostat results in increased expression of ATF3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp13a4 |
ATPase 13A4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp23 |
ATP23 metallopeptidase and ATP synthase assembly factor homolog |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ATP23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862
|
|
G |
Atp2c2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA panobinostat results in increased expression of ATP2C2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA panobinostat results in decreased expression of ATP6V0A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA panobinostat results in increased expression of ATP6V0A4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA panobinostat results in increased expression of ATP6V0D2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA panobinostat results in increased expression of ATP8B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atp8b3 |
ATPase phospholipid transporting 8B3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA panobinostat results in increased expression of ATP8B3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:9,175,544...9,195,449
Ensembl chr 7:9,175,391...9,195,442
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA panobinostat results in decreased expression of ATP9A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
|
|
G |
Axin2 |
axin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA panobinostat results in increased expression of AXIN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA panobinostat results in increased expression of B3GNT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
Bace2 |
beta-secretase 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BACE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bag2 |
BAG cochaperone 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA panobinostat results in increased expression of BAG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:35,970,033...35,980,721
|
|
G |
Bag5 |
BAG cochaperone 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BAMBI mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Batf3 |
basic leucine zipper ATF-like transcription factor 3 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] |
CTD |
PMID:18445700 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz1a |
bromodomain adjacent to zinc finger domain, 1A |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA panobinostat results in increased expression of BAZ1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
|
|
G |
Bcl11a |
BCL11 transcription factor A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BCL11A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression decreases expression multiple interactions |
ISO |
panobinostat affects the expression of BCL2 mRNA panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA] |
CTD |
PMID:24435446 PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions decreases expression increases expression |
ISO |
(+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] panobinostat results in decreased expression of BCL2L11 mRNA panobinostat results in increased expression of BCL2L11 protein |
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Begain |
brain-enriched guanylate kinase-associated |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA panobinostat results in decreased expression of BEGAIN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:127,943,651...127,979,876
Ensembl chr 6:127,943,651...127,979,841
|
|
G |
Best4 |
bestrophin 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA panobinostat results in decreased expression of BEST4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:130,622,194...130,629,045
Ensembl chr 5:130,623,438...130,627,099
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BHLHE40 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Panobinostat results in decreased expression of BIRC5 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with Panobinostat] affects the expression of BMAL2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
ISO |
Panobinostat results in increased expression of BMF mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA panobinostat results in increased expression of BMP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA panobinostat results in increased expression of BMP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA panobinostat results in increased expression of BMP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA panobinostat results in increased expression of BMP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmper |
BMP-binding endothelial regulator |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA panobinostat results in increased expression of BMPER mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bnc2 |
basonuclin zinc finger protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BNC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:98,687,410...99,079,426
|
|
G |
Bnipl |
BCL2 interacting protein like |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA panobinostat results in increased expression of BNIPL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:182,818,593...182,830,421
Ensembl chr 2:182,818,595...182,828,588
|
|
G |
Boc |
BOC cell adhesion associated, oncogene regulated |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA panobinostat results in increased expression of BOC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:56,122,697...56,198,060
Ensembl chr11:56,122,750...56,198,059
|
|
G |
Bri3bp |
Bri3 binding protein |
increases expression |
ISO |
panobinostat results in increased expression of BRI3BP mRNA |
CTD |
PMID:26272509 |
|
NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572
|
|
G |
Brinp1 |
BMP/retinoic acid inducible neural specific 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BRINP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:82,348,501...82,550,506
Ensembl chr 5:82,348,930...82,493,150
|
|
G |
Brip1 |
BRCA1 interacting DNA helicase 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324
|
|
G |
Bspry |
B-box and SPRY domain containing |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of BSPRY mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
|
|
G |
C11h3orf52 |
similar to human chromosome 3 open reading frame 52 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of C3ORF52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:55,166,986...55,192,273
Ensembl chr11:55,166,678...55,192,292
|
|
G |
C13h1orf53 |
similar to human chromosome 1 open reading frame 53 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1ORF53 mRNA panobinostat results in decreased expression of C1ORF53 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:50,413,785...50,418,974
Ensembl chr13:50,413,785...50,419,120
|
|
G |
C14h4orf19 |
similar to human chromosome 4 open reading frame 19 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:44,387,386...44,478,344
Ensembl chr14:44,387,393...44,478,041
|
|
G |
C19h16orf87 |
similar to human chromosome 16 open reading frame 87 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C16ORF87 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:21,626,390...21,653,869
Ensembl chr19:21,626,914...21,654,255
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA panobinostat results in increased expression of C1GALT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831
|
|
G |
C1h19orf33 |
similar to human chromosome 19 open reading frame 33 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA Panobinostat results in increased expression of C19ORF33 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:84,549,830...84,550,666
Ensembl chr 1:84,549,831...84,550,664
|
|
G |
C1qtnf4 |
C1q and TNF related 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA panobinostat results in decreased expression of C1QTNF4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA panobinostat results in decreased expression of C2CD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:37,225,321...37,289,741
Ensembl chr11:37,227,415...37,289,739
|
|
G |
C2h3orf33 |
similar to human chromosome 3 open reading frame 33 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of C3ORF33 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C3ORF33 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:148,376,598...148,404,343
Ensembl chr 2:148,380,581...148,404,387
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C3h11orf96 |
similar to human chromosome 11 open reading frame 96 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA panobinostat results in increased expression of C11ORF96 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:79,920,129...79,921,523
|
|
G |
C4h2orf68 |
similar to human chromosome 2 open reading frame 68 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of C2ORF68 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:104,402,553...104,408,317
Ensembl chr 4:104,402,588...104,408,320
|
|
G |
C5h8orf34 |
similar to human chromosome 8 open reading frame 34 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA panobinostat results in increased expression of C8ORF34 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:7,238,853...7,776,769
|
|
G |
C7h12orf56 |
similar to human chromosome 12 open reading frame 56 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of C12ORF56 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C12ORF56 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:57,170,406...57,220,930
Ensembl chr 7:57,170,992...57,220,925
|
|
G |
C8h11orf52 |
similar to human chromosome 11 open reading frame 52 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:51,081,342...51,088,333
Ensembl chr 8:51,081,342...51,094,533
|
|
G |
C9h6orf141 |
similar to human chromosome 6 open reading frame 141 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of C6ORF141 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:20,024,916...20,029,094
Ensembl chr 9:20,024,916...20,029,094
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CACNA2D1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CACNB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:77,564,630...77,910,000
Ensembl chr17:77,564,460...77,909,106
|
|
G |
Cadm4 |
cell adhesion molecule 4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CADM4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:80,075,163...80,097,423
Ensembl chr 1:80,075,202...80,097,423
|
|
G |
Calb2 |
calbindin 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CALB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CALCA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Capn6 |
calpain 6 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CAPN6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:107,380,774...107,405,489
Ensembl chr X:107,380,774...107,405,489
|
|
G |
Car12 |
carbonic anhydrase 12 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CA12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car13 |
carbonic anhydrase 13 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
|
|
G |
Car4 |
carbonic anhydrase 4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Car8 |
carbonic anhydrase 8 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein |
CTD |
PMID:22923501 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein] panobinostat results in increased expression of CASP8 mRNA |
CTD |
PMID:21791302 PMID:22923501 PMID:26272509 PMID:27188386 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein |
CTD |
PMID:22923501 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cblc |
Cbl proto-oncogene C |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CBLC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:79,439,975...79,456,755
Ensembl chr 1:79,439,977...79,456,755
|
|
G |
Cc2d2a |
coiled-coil and C2 domain containing 2A |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr14:67,349,004...67,435,883
Ensembl chr14:67,351,353...67,435,949
|
|
G |
Ccdc136 |
coiled-coil domain containing 136 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CCDC136 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:57,997,825...58,027,598
Ensembl chr 4:57,997,853...58,027,646
|
|
G |
Ccdc177 |
coiled-coil domain containing 177 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CCDC177 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:100,404,526...100,411,112
Ensembl chr 6:100,404,413...100,412,850
|
|
G |
Ccdc69 |
coiled-coil domain containing 69 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA panobinostat results in increased expression of CCDC69 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,173,282...39,199,878
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CCKBR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CCL26 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccn3 |
cellular communication network factor 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CCNG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccnt2 |
cyclin T2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CCNT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:39,251,573...39,293,172
Ensembl chr13:39,251,573...39,292,019
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA panobinostat results in increased expression of CD24 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Panobinostat results in increased expression of CD274 protein |
CTD |
PMID:26775640 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd44 |
CD44 molecule |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CD44 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd52 |
CD52 molecule |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CD52 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA panobinostat results in increased expression of CD55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd74 |
CD74 molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA panobinostat results in increased expression of CD74 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd9 |
CD9 molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA panobinostat results in increased expression of CD9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA panobinostat results in decreased expression of CDC42EP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdc42ep5 |
CDC42 effector protein 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA panobinostat results in increased expression of CDC42EP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:70,035,921...70,038,990
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA panobinostat results in increased expression of CDH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh10 |
cadherin 10 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA panobinostat results in increased expression of CDH10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
|
|
G |
Cdh18 |
cadherin 18 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CDH18 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:73,345,005...73,820,138
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA panobinostat results in decreased expression of CDH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh3 |
cadherin 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CDH3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdh8 |
cadherin 8 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CDH8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:5,494,038...5,901,810
Ensembl chr19:5,494,174...5,895,669
|
|
G |
Cdk19 |
cyclin-dependent kinase 19 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions increases expression |
ISO |
[(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA panobinostat results in increased expression of CDK6 mRNA |
CTD |
PMID:24435446 PMID:26272509 PMID:27188386 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
panobinostat results in increased expression of CDKN1A protein |
CTD |
PMID:18445700 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
panobinostat results in increased expression of CDKN1B protein |
CTD |
PMID:18445700 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CDON mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA panobinostat results in increased expression of CEBPB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CEBPD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celf5 |
CUGBP, Elav-like family member 5 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322
|
|
G |
Cep85l |
centrosomal protein 85-like |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA panobinostat results in increased expression of CEP85L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:32,568,417...32,739,449
Ensembl chr20:32,572,741...32,739,516
|
|
G |
Cfap91 |
cilia and flagella associated protein 91 |
decreases expression multiple interactions |
ISO |
Panobinostat results in decreased expression of CFAP91 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:62,413,613...62,457,281
Ensembl chr11:62,413,602...62,457,293
|
|
G |
Cfap95 |
cilia and flagella associated protein 95 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CFAP95 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:221,123,786...221,242,963
Ensembl chr 1:221,131,813...221,242,963
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cgnl1 |
cingulin-like 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CGNL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:72,273,401...72,424,842
Ensembl chr 8:72,275,645...72,422,917
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
panobinostat results in increased expression of CHAC1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chga |
chromogranin A |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA panobinostat results in increased expression of CHGA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chodl |
chondrolectin |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA panobinostat results in increased expression of CHODL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA panobinostat results in increased expression of CHRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CHST15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
|
|
G |
Chst4 |
carbohydrate sulfotransferase 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA panobinostat results in increased expression of CHST4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:37,993,471...38,002,123
Ensembl chr19:37,991,417...38,003,608
|
|
G |
Chsy1 |
chondroitin sulfate synthase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA panobinostat results in increased expression of CHSY1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601
|
|
G |
Cimap3 |
ciliary microtubule associated protein 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:193,475,782...193,493,139
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA panobinostat results in increased expression of CITED2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Cldn1 |
claudin 1 |
increases expression |
ISO |
panobinostat results in increased expression of CLDN1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn23 |
claudin 23 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CLDN23 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523
|
|
G |
Cldn4 |
claudin 4 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CLDN4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Cldn6 |
claudin 6 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA panobinostat results in increased expression of CLDN6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:12,710,302...12,713,987
Ensembl chr10:12,709,960...12,715,973
|
|
G |
Cldn7 |
claudin 7 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CLDN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Clgn |
calmegin |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CLGN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clic6 |
chloride intracellular channel 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CLIC6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:31,737,813...31,780,360
Ensembl chr11:31,737,813...31,780,061
|
|
G |
Clp1 |
cleavage factor polyribonucleotide kinase subunit 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:69,806,774...69,818,633
Ensembl chr 3:69,806,778...69,810,421
|
|
G |
Clstn2 |
calsyntenin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA panobinostat results in increased expression of CLSTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731
|
|
G |
Cltrn |
collectrin, amino acid transport regulator |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA panobinostat results in decreased expression of CLTRN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349
|
|
G |
Clu |
clusterin |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CLU mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CNKSR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555
|
|
G |
Cnmd |
chondromodulin |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CNMD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297
|
|
G |
Cnot4 |
CCR4-NOT transcription complex, subunit 4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:63,712,770...63,814,355
Ensembl chr 4:63,712,770...63,814,360
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA panobinostat results in increased expression of CNRIP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:91,462,877...91,492,739
Ensembl chr14:91,462,647...91,492,735
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA panobinostat results in increased expression of CNTN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cntn2 |
contactin 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CNTN2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:43,942,868...43,975,973
Ensembl chr13:43,947,265...43,975,887
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA panobinostat results in increased expression of COBL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA panobinostat results in increased expression of COBLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:49,753,260...49,915,168
Ensembl chr 3:49,753,262...49,915,194
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
increases expression |
ISO |
panobinostat results in increased expression of COL11A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA panobinostat results in increased expression of COL14A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA panobinostat results in increased expression of COL1A2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col23a1 |
collagen type XXIII alpha 1 chain |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of COL23A1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
increases expression |
ISO |
panobinostat results in increased expression of COL5A2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA panobinostat results in increased expression of COL5A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA panobinostat results in increased expression of COL6A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA panobinostat results in increased expression of COL6A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA panobinostat results in increased expression of COL9A3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Colec12 |
collectin sub-family member 12 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of COLEC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:732,950...920,620
Ensembl chr18:732,950...920,618
|
|
G |
Colgalt2 |
collagen beta(1-O)galactosyltransferase 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of COLGALT2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:64,523,641...64,628,295
Ensembl chr13:64,523,658...64,627,549
|
|
G |
Comtd1 |
catechol-O-methyltransferase domain containing 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of COMTD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,459,783...2,462,895
|
|
G |
Coro2a |
coronin 2A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CORO2A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035
|
|
G |
Cpe |
carboxypeptidase E |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CPE mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cped1 |
cadherin-like and PC-esterase domain containing 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CPED1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:50,516,712...50,789,651
Ensembl chr 4:50,516,819...50,788,674
|
|
G |
Cpne4 |
copine 4 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CPNE4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068
|
|
G |
Cpxm2 |
carboxypeptidase X (M14 family), member 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CPXM2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220
|
|
G |
Cr1l |
complement C3b/C4b receptor 1 like |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CR1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CR2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA panobinostat results in increased expression of CRABP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Crip1 |
cysteine rich protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620
|
|
G |
Cripto |
cripto, EGF-CFC family member |
increases expression |
ISO |
Panobinostat results in increased expression of CRIPTO mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308
|
|
G |
Crispld1 |
cysteine-rich secretory protein LCCL domain containing 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CRISPLD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926
|
|
G |
Cryba1 |
crystallin, beta A1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA panobinostat results in decreased expression of CRYBA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:62,608,373...62,614,726
Ensembl chr10:62,608,383...62,614,726
|
|
G |
Cryba4 |
crystallin, beta A4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CRYBA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
|
|
G |
Crybg1 |
crystallin beta-gamma domain containing 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA panobinostat results in increased expression of CRYBG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA panobinostat results in decreased expression of CSPG5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758
|
|
G |
Csrnp3 |
cysteine and serine rich nuclear protein 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:50,498,379...50,695,598
Ensembl chr 3:50,498,633...50,685,950
|
|
G |
Cthrc1 |
collagen triple helix repeat containing 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA panobinostat results in decreased expression of CTNND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764
|
|
G |
Cul3 |
cullin 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of CUL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA panobinostat results in increased expression of CX3CL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA panobinostat results in increased expression of CXCL12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA panobinostat results in increased expression of CXCL14 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA panobinostat results in increased expression of CXXC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA panobinostat results in increased expression of CYP1A1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of CYP1B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyren |
cell cycle regulator of NHEJ |
decreases expression |
ISO |
panobinostat results in decreased expression of CYREN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:63,547,311...63,553,394
Ensembl chr 4:63,547,335...63,551,602
|
|
G |
Cyria |
CYFIP related Rac1 interactor A |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA Panobinostat results in increased expression of CYRIA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:35,045,208...35,150,669
Ensembl chr 6:35,045,208...35,150,668
|
|
G |
Dab1 |
DAB adaptor protein 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA panobinostat results in decreased expression of DAB1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Dach2 |
dachshund family transcription factor 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DACH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:78,718,963...79,018,023
Ensembl chr X:78,451,593...79,017,592
|
|
G |
Dact1 |
dishevelled-binding antagonist of beta-catenin 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA panobinostat results in increased expression of DACT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:89,790,644...89,817,906
|
|
G |
Dazl |
deleted in azoospermia-like |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA panobinostat results in decreased expression of DAZL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:10,695,593...10,712,330
Ensembl chr 9:10,695,592...10,712,323
|
|
G |
Dcaf12l2 |
DDB1 and CUL4 associated factor 12-like 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA panobinostat results in decreased expression of DCAF12L2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:123,293,761...123,296,550
Ensembl chr X:123,294,744...123,296,156
|
|
G |
Dcaf4 |
DDB1 and CUL4 associated factor 4 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DCAF4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA panobinostat results in increased expression of DCC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA panobinostat results in increased expression of DCLK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dclk2 |
doublecortin-like kinase 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA panobinostat results in decreased expression of DCLK2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:172,202,733...172,338,411
Ensembl chr 2:172,208,706...172,338,250
|
|
G |
Dcun1d4 |
defective in cullin neddylation 1 domain containing 4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:34,652,723...34,733,122
Ensembl chr14:34,652,723...34,733,207
|
|
G |
Dennd1a |
DENN domain containing 1A |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA panobinostat results in decreased expression of DENND1A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:21,564,749...22,052,062
|
|
G |
Dennd1b |
DENN domain containing 1B |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA panobinostat results in decreased expression of DENND1B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:50,545,324...50,772,922
Ensembl chr13:50,545,836...50,770,601
|
|
G |
Dennd2a |
DENN domain containing 2A |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA panobinostat results in decreased expression of DENND2A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:68,233,016...68,332,235
Ensembl chr 4:68,233,958...68,332,105
|
|
G |
Dennd4a |
DENN domain containing 4A |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA panobinostat results in increased expression of DENND4A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression |
ISO |
panobinostat results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Depdc7 |
DEP domain containing 7 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DEPDC7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DEPTOR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DHRS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Diaph2 |
diaphanous-related formin 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DIAPH2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869
|
|
G |
Dipk1c |
divergent protein kinase domain 1C |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of DIPK1C mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:78,087,972...78,109,910
Ensembl chr18:78,087,991...78,109,904
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DLC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of DLK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dlx3 |
distal-less homeobox 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DLX3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:80,064,489...80,069,891
Ensembl chr10:80,064,489...80,069,872
|
|
G |
Dlx6 |
distal-less homeobox 6 |
decreases expression |
ISO |
panobinostat results in decreased expression of DLX6 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343
|
|
G |
Dmrta2 |
DMRT-like family A2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA panobinostat results in increased expression of DMRTA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:124,805,883...124,811,694
Ensembl chr 5:124,805,883...124,811,630
|
|
G |
Dmxl1 |
Dmx-like 1 |
increases expression |
ISO |
Panobinostat results in increased expression of DMXL1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:85,586,987...85,902,637
|
|
G |
Dock5 |
dedicator of cytokinesis 5 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DOCK5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:41,979,728...42,158,733
Ensembl chr15:41,979,729...42,158,649
|
|
G |
Dock9 |
dedicator of cytokinesis 9 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DOCK9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:98,611,518...98,883,306
Ensembl chr15:98,618,084...98,883,153
|
|
G |
Dok5 |
docking protein 5 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:159,515,893...159,652,810
|
|
G |
Dppa5 |
developmental pluripotency associated 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA panobinostat results in increased expression of DPPA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:79,215,341...79,217,282
Ensembl chr 8:79,215,362...79,216,570 Ensembl chr 7:79,215,362...79,216,570 Ensembl chr 1:79,215,362...79,216,570 Ensembl chr 3:79,215,362...79,216,570
|
|
G |
Dsc2 |
desmocollin 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DSC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dst |
dystonin |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of DST mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Dtwd1 |
DTW domain containing 1 |
decreases expression |
ISO |
Panobinostat results in decreased expression of DTWD1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 3:113,392,402...113,409,322
Ensembl chr 3:113,392,457...113,408,105
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of DUSP10 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp23 |
dual specificity phosphatase 23 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr13:85,097,899...85,100,054
Ensembl chr13:85,097,899...85,100,093
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of DUSP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA panobinostat results in increased expression of DUSP5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA panobinostat results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Dyrk3 |
dual specificity tyrosine phosphorylation regulated kinase 3 |
increases expression |
ISO |
Panobinostat results in increased expression of DYRK3 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA panobinostat results in decreased expression of E2F2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Eaf2 |
ELL associated factor 2 |
increases expression |
ISO |
Panobinostat results in increased expression of EAF2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Ebf1 |
EBF transcription factor 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA panobinostat results in increased expression of EBF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:29,095,858...29,489,142
Ensembl chr10:29,099,933...29,487,665
|
|
G |
Ebi3 |
Epstein-Barr virus induced 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:774,252...787,544
Ensembl chr 9:783,617...787,544
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA panobinostat results in decreased expression of ECPAS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EDN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EDNRA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA panobinostat results in increased expression of EDNRB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA panobinostat results in increased expression of EFNA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Efna5 |
ephrin A5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA panobinostat results in decreased expression of EFNA5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:102,316,753...102,595,480
Ensembl chr 9:102,320,295...102,597,413
|
|
G |
Egf |
epidermal growth factor |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of EGF mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfl8 |
EGF-like-domain, multiple 8 |
increases expression |
ISO |
panobinostat results in increased expression of EGFL8 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr20:4,132,930...4,136,024
Ensembl chr20:4,133,629...4,136,018
|
|
G |
Eif3m |
eukaryotic translation initiation factor 3, subunit M |
decreases expression |
ISO |
panobinostat results in decreased expression of EIF3M mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:91,424,754...91,442,358
Ensembl chr 3:91,416,325...91,442,392
|
|
G |
Eif4e3 |
eukaryotic translation initiation factor 4E family member 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of EIF4E3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ELF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ELF3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ELF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ELK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
|
|
G |
Elmod1 |
ELMO domain containing 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ELMOD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ELOVL2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848
|
|
G |
Elp4 |
elongator acetyltransferase complex subunit 4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ELP4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:92,162,271...92,385,251
Ensembl chr 3:92,162,280...92,385,243
|
|
G |
Emilin3 |
elastin microfibril interfacer 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of EMILIN3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:149,558,785...149,564,785
Ensembl chr 3:149,558,970...149,564,785
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EMP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA panobinostat results in increased expression of ENPP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Eogt |
EGF domain specific O-linked N-acetylglucosamine transferase |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA panobinostat results in increased expression of EOGT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:129,718,897...129,756,558
Ensembl chr 4:129,718,901...129,756,445
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EPAS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EPB41L3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Epb41l5 |
erythrocyte membrane protein band 4.1 like 5 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EPB41L5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA panobinostat results in increased expression of EPCAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Epha1 |
Eph receptor A1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA panobinostat results in increased expression of EPHA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Epha4 |
Eph receptor A4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA panobinostat results in decreased expression of EPHA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Epha7 |
Eph receptor A7 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of EPHA7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:42,975,405...43,127,112
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of EPHB2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Epn3 |
epsin 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:79,438,978...79,449,516
Ensembl chr10:79,438,978...79,447,356
|
|
G |
Eps8l2 |
EPS8-like 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:196,446,260...196,471,544
Ensembl chr 1:196,446,287...196,471,541
|
|
G |
Epsti1 |
epithelial stromal interaction 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA panobinostat results in increased expression of EPSTI1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA panobinostat results in decreased expression of ERAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA panobinostat results in increased expression of ERBB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erp27 |
endoplasmic reticulum protein 27 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA panobinostat results in increased expression of ERP27 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:169,804,656...169,821,660
Ensembl chr 4:169,804,658...169,821,660
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ESRP1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Esrp2 |
epithelial splicing regulatory protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA panobinostat results in increased expression of ESRP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:34,034,559...34,041,726
Ensembl chr19:34,034,559...34,041,726
|
|
G |
Etnk1 |
ethanolamine kinase 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ETNK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ETS1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA panobinostat results in decreased expression of ETV1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775
|
|
G |
Ext1 |
exostosin glycosyltransferase 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA panobinostat results in decreased expression of EXT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357
|
|
G |
Ezr |
ezrin |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA panobinostat results in increased expression of EZR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA panobinostat results in increased expression of F2RL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA panobinostat results in decreased expression of F2RL2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA panobinostat results in increased expression of FABP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fam110b |
family with sequence similarity 110, member B |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828
|
|
G |
Fam124a |
family with sequence similarity 124 member A |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FAM124A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:36,799,836...36,855,062
Ensembl chr15:36,799,877...36,853,683
|
|
G |
Fam13c |
family with sequence similarity 13, member C |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA panobinostat results in increased expression of FAM13C mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592
|
|
G |
Fam149a |
family with sequence similarity 149, member A |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FAM149A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:46,855,377...46,914,553
Ensembl chr16:46,854,635...46,912,066
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
affects expression multiple interactions |
ISO |
panobinostat affects the expression of FAM163A mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FAM168A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
|
|
G |
Fam241a |
family with sequence similarity 241 member A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FAM43A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
|
|
G |
Fam89a |
family with sequence similarity 89, member A |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FAM89A mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:52,710,002...52,722,630
Ensembl chr19:52,710,019...52,722,631
|
|
G |
Fank1 |
fibronectin type III and ankyrin repeat domains 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA panobinostat results in decreased expression of FANK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:188,577,512...188,685,501
Ensembl chr 1:188,577,575...188,685,504
|
|
G |
Fat3 |
FAT atypical cadherin 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FAT3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:12,691,470...13,274,336
Ensembl chr 8:12,694,019...13,273,135
|
|
G |
Faxc |
failed axon connections homolog, metaxin like GST domain containing |
affects expression multiple interactions |
ISO |
panobinostat affects the expression of FAXC mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 5:35,480,137...35,539,741
Ensembl chr 5:35,480,402...35,544,446
|
|
G |
Fbln7 |
fibulin 7 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FBLN7 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:116,111,677...116,147,983
|
|
G |
Fbn1 |
fibrillin 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA panobinostat results in decreased expression of FBN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxl13 |
F-box and leucine-rich repeat protein 13 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:13,414,880...13,607,079
Ensembl chr 4:13,414,926...13,641,494
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FBXO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fbxo8 |
F-box protein 8 |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr16:33,665,305...33,711,215
Ensembl chr16:33,665,306...33,711,272
|
|
G |
Fbxo9 |
f-box protein 9 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949
|
|
G |
Fermt1 |
FERM domain containing kindlin 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FERMT1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:120,171,301...120,213,555
Ensembl chr 3:120,171,561...120,213,555
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA panobinostat results in decreased expression of FEZ1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fezf2 |
Fez family zinc finger 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA panobinostat results in decreased expression of FEZF2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:12,768,614...12,777,554
Ensembl chr15:12,773,762...12,777,554
|
|
G |
Fgd5 |
FYVE, RhoGEF and PH domain containing 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA panobinostat results in increased expression of FGD5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:124,497,061...124,594,564
Ensembl chr 4:124,497,068...124,594,563
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FGF19 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FGF8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of FGF9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfbp3 |
fibroblast growth factor binding protein 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FGFBP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:234,644,019...234,646,547
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA panobinostat results in increased expression of FGFR3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fhod3 |
formin homology 2 domain containing 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA panobinostat results in decreased expression of FHOD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:15,993,079...16,425,796
Ensembl chr18:15,993,324...16,425,796
|
|
G |
Fign |
fidgetin, microtubule severing factor |
affects expression multiple interactions |
ISO |
panobinostat affects the expression of FIGN mRNA (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 3:48,637,510...48,760,772
Ensembl chr 3:48,642,496...48,760,787
|
|
G |
Fjx1 |
four-jointed box kinase 1 |
decreases expression |
ISO |
panobinostat results in decreased expression of FJX1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 3:88,774,220...88,776,321
Ensembl chr 3:88,774,220...88,776,321
|
|
G |
Flnb |
filamin B |
increases expression |
ISO |
panobinostat results in increased expression of FLNB mRNA |
CTD |
PMID:26272509 |
|
NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
|
|
G |
Flrt2 |
fibronectin leucine rich transmembrane protein 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA panobinostat results in decreased expression of FLRT2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA panobinostat results in increased expression of FLT1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA panobinostat results in decreased expression of FNDC5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731
|
|
G |
Foxc1 |
forkhead box C1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FOXC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803
|
|
G |
Foxc2 |
forkhead box C2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FOXC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Foxd3 |
forkhead box D3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FOXD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:114,335,408...114,336,817
|
|
G |
Foxh1 |
forkhead box H1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FOXH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:108,387,969...108,391,566
Ensembl chr 7:108,387,969...108,390,049
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of FOXO1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fras1 |
Fraser extracellular matrix complex subunit 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr14:12,791,407...13,200,862
Ensembl chr14:12,793,599...13,200,726
|
|
G |
Frem1 |
Fras1 related extracellular matrix 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA panobinostat results in increased expression of FREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:97,322,538...97,469,543
|
|
G |
Frrs1l |
ferric-chelate reductase 1-like |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA panobinostat results in decreased expression of FRRS1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:71,659,284...71,690,108
|
|
G |
Frzb |
frizzled-related protein |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA panobinostat results in decreased expression of FRZB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA panobinostat results in increased expression of FUT4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Fut9 |
fucosyltransferase 9 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA panobinostat results in decreased expression of FUT9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:39,351,815...39,565,256
Ensembl chr 5:39,351,819...39,565,130
|
|
G |
Fzd10 |
frizzled class receptor 10 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA panobinostat results in increased expression of FZD10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA panobinostat results in decreased expression of FZD2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
Fzd3 |
frizzled class receptor 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA panobinostat results in decreased expression of FZD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:39,421,366...39,488,369
Ensembl chr15:39,421,355...39,488,369
|
|
G |
Fzd5 |
frizzled class receptor 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA panobinostat results in decreased expression of FZD5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA panobinostat results in increased expression of FZD7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Fzd8 |
frizzled class receptor 8 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA panobinostat results in increased expression of GABRB2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA panobinostat results in increased expression of GABRB3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gabrp |
gamma-aminobutyric acid type A receptor subunit pi |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:18,143,031...18,169,595
Ensembl chr10:18,143,038...18,169,516
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA panobinostat results in increased expression of GAD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA] panobinostat results in increased expression of GADD45A mRNA |
CTD |
PMID:23681230 PMID:26272509 PMID:27188386 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GADD45B mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions increases expression |
ISO |
GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA] |
CTD |
PMID:23681230 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Galnt18 |
polypeptide N-acetylgalactosaminyltransferase 18 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA panobinostat results in increased expression of GALNT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA panobinostat results in increased expression of GALNT3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA panobinostat results in increased expression of GAP43 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Garin1b |
golgi associated RAB2 interactor 1B |
decreases expression |
ISO |
Panobinostat results in decreased expression of GARIN1B mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 4:57,915,184...57,938,593
Ensembl chr 4:57,920,790...57,938,591
|
|
G |
Gas7 |
growth arrest specific 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA panobinostat results in increased expression of GAS7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA panobinostat results in increased expression of GATA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA panobinostat results in increased expression of GATA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA panobinostat results in decreased expression of GATA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gata6 |
GATA binding protein 6 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gbx2 |
gastrulation brain homeobox 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GBX2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,509,633...90,512,212
Ensembl chr 9:90,509,633...90,512,212
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GCHFR mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080
|
|
G |
Gdf10 |
growth differentiation factor 10 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
|
|
G |
Gja3 |
gap junction protein, alpha 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GJA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:31,181,360...31,206,820
Ensembl chr15:31,181,369...31,206,810
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gje1 |
gap junction protein, epsilon 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:9,085,789...9,088,204
Ensembl chr 1:9,086,348...9,088,138
|
|
G |
Gkap1 |
G kinase anchoring protein 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA panobinostat results in decreased expression of GKAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679
|
|
G |
Glb1l |
galactosidase, beta 1-like |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:76,693,325...76,705,548
Ensembl chr 9:76,695,173...76,705,510
|
|
G |
Glcci1 |
glucocorticoid induced 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GLCCI1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:36,307,956...36,635,614
Ensembl chr 4:36,307,903...36,635,612
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GLIS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:225,976,029...226,395,849
Ensembl chr 1:225,976,326...226,395,899
|
|
G |
Glrx2 |
glutaredoxin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA panobinostat results in increased expression of GLRX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831
|
|
G |
Gls |
glutaminase |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA panobinostat results in increased expression of GLS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA panobinostat results in increased expression of GNAS mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gng11 |
G protein subunit gamma 11 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA panobinostat results in increased expression of GNG11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,023,003...32,028,442
|
|
G |
Gng8 |
G protein subunit gamma 8 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA panobinostat results in decreased expression of GNG8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371
|
|
G |
Gnl3l |
G protein nucleolar 3 like |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA |
CTD |
PMID:21791302 |
|
NCBI chr X:19,961,277...19,994,454
Ensembl chr X:19,958,603...19,994,508
|
|
G |
Gpc3 |
glypican 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GPC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpc4 |
glypican 4 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GPC4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:131,644,711...131,755,349
Ensembl chr X:131,644,704...131,755,284
|
|
G |
Gpc6 |
glypican 6 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA panobinostat results in decreased expression of GPC6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:94,030,218...95,027,883
Ensembl chr15:94,029,884...95,024,006
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1 like |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GPD1L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:114,591,103...114,620,771
Ensembl chr 8:114,588,487...114,620,723
|
|
G |
Gpr173 |
G-protein coupled receptor 173 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GPR173 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:21,446,261...21,471,119
Ensembl chr X:21,447,361...21,471,498
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
decreases expression |
ISO |
Panobinostat results in decreased expression of GPR183 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GPR27 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GPR37 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:54,138,870...54,161,001
|
|
G |
Grem1 |
gremlin 1, DAN family BMP antagonist |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GREM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082
|
|
G |
Grhl1 |
grainyhead-like transcription factor 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301
|
|
G |
Grhl2 |
grainyhead-like transcription factor 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258
|
|
G |
Grhl3 |
grainyhead-like transcription factor 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GRHL3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GRIA3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of GRIK3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grm3 |
glutamate metabotropic receptor 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA panobinostat results in decreased expression of GRM3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:24,364,854...24,643,972
Ensembl chr 4:24,365,115...24,609,804
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA] |
CTD |
PMID:26733615 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gypc |
glycophorin C |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of GYPC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein] |
CTD |
PMID:22923501 PMID:23681230 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression multiple interactions |
ISO |
Panobinostat results in decreased expression of H2BC12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:42,485,699...42,486,162
|
|
G |
H3f4 |
H3.4 histone, cluster member |
increases acetylation |
ISO |
Panobinostat results in increased acetylation of H3-4 protein |
CTD |
PMID:19215824 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
Hacd1 |
3-hydroxyacyl-CoA dehydratase 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HACD1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA panobinostat results in increased expression of HAPLN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Has2 |
hyaluronan synthase 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA panobinostat results in increased expression of HAS2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA panobinostat results in increased expression of HDAC8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression |
ISO |
Panobinostat results in decreased expression of HDAC9 mRNA |
CTD |
PMID:30481203 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA panobinostat results in decreased expression of HEG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
|
|
G |
Hes2 |
hes family bHLH transcription factor 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HES2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:162,667,190...162,668,235
Ensembl chr 5:162,667,190...162,668,235
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of HES5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hesx1 |
HESX homeobox 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of HESX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,191,852...2,193,957
Ensembl chr16:2,191,852...2,193,957
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA panobinostat results in increased expression of HEY2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hhip |
Hedgehog-interacting protein |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:27,863,684...27,952,528
Ensembl chr19:27,863,213...27,952,528
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
increases expression |
ISO |
Panobinostat results in increased expression of HIP1 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hk1 |
hexokinase 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HK1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmces |
5-hydroxymethylcytosine binding, ES cell specific |
increases expression |
ISO |
Panobinostat results in increased expression of HMCES mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 4:120,392,812...120,415,616
Ensembl chr 4:120,366,542...120,415,616
|
|
G |
Hmgcll1 |
3-hydroxy-3-methylglutaryl-CoA lyase like 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of HMGCLL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:76,757,301...76,887,300
Ensembl chr 8:76,757,497...76,886,816
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA panobinostat results in increased expression of HMOX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmx2 |
H6 family homeobox 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:186,319,110...186,326,771
|
|
G |
Hnmt |
histamine N-methyltransferase |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HNMT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:6,591,804...6,623,821
Ensembl chr 3:6,591,463...6,624,012
|
|
G |
Hnrnpr |
heterogeneous nuclear ribonucleoprotein R |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:148,542,999...148,574,888
Ensembl chr 5:148,543,044...148,574,867
|
|
G |
Homez |
homeobox and leucine zipper encoding |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:28,321,633...28,339,486
Ensembl chr15:28,320,819...28,339,745
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpdl |
4-hydroxyphenylpyruvate dioxygenase-like |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA panobinostat results in increased expression of HPDL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:130,286,631...130,288,233
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hps1 |
HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA panobinostat results in increased expression of HPS1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HRK mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hs3st3b1 |
heparan sulfate-glucosamine 3-sulfotransferase 3B1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of HS3ST3B1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of HSPA4L mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ICAM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id4 |
inhibitor of DNA binding 4 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA panobinostat results in increased expression of ID4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:16,389,387...16,391,956
Ensembl chr17:16,389,387...16,392,470
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA panobinostat results in increased expression of IDH3A mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ier3 |
immediate early response 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of IER3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifi30 |
IFI30, lysosomal thiol reductase |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA panobinostat results in increased expression of IFI30 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
increases expression multiple interactions |
ISO |
Panobinostat results in increased expression of IFITM1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Ifnar2 |
interferon alpha and beta receptor subunit 2 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr11:30,613,576...30,645,958
Ensembl chr11:30,613,767...30,668,124
|
|
G |
Ift25 |
intraflagellar transport 25 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IFT25 mRNA Panobinostat results in decreased expression of IFT25 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421
|
|
G |
Igdcc3 |
immunoglobulin superfamily, DCC subclass, member 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of IGDCC3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:65,661,165...65,707,961
Ensembl chr 8:65,661,196...65,707,959
|
|
G |
Igf2 |
insulin-like growth factor 2 |
increases expression |
ISO |
panobinostat results in increased expression of IGF2 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
decreases expression |
ISO |
panobinostat results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA panobinostat results in increased expression of IGFBP7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Igsf21 |
immunoglobin superfamily, member 21 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:152,287,834...152,512,174
Ensembl chr 5:152,287,835...152,512,174
|
|
G |
Il17rd |
interleukin 17 receptor D |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of IL17RD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:2,228,438...2,295,122
Ensembl chr16:2,228,287...2,292,556
|
|
G |
Il1rapl1 |
interleukin 1 receptor accessory protein-like 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of IL1RAPL1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of IL20RB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of IL27RA mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938
|
|
G |
Il3ra |
interleukin 3 receptor subunit alpha |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA Panobinostat results in increased expression of IL3RA mRNA |
CTD |
PMID:21791302 PMID:33770205 |
|
NCBI chr12:16,318,081...16,323,781
Ensembl chr12:16,318,081...16,323,484
|
|
G |
Inf2 |
inverted formin 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA panobinostat results in increased expression of INF2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941
|
|
G |
Inhbe |
inhibin subunit beta E |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA panobinostat results in increased expression of INHBE mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase type II B |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Inpp5f |
inositol polyphosphate-5-phosphatase F |
increases expression |
ISO |
Panobinostat results in increased expression of INPP5F mRNA |
CTD |
PMID:33770205 |
|
NCBI chr 1:183,190,480...183,270,276
Ensembl chr 1:183,190,480...183,270,276
|
|
G |
Insc |
INSC, spindle orientation adaptor protein |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of INSC mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:168,993,032...169,100,438
Ensembl chr 1:168,993,032...169,100,433
|
|
G |
Iqca1 |
IQ motif containing with AAA domain 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA panobinostat results in increased expression of IQCA1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:90,626,744...90,742,618
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA panobinostat results in increased expression of IQGAP1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Irf6 |
interferon regulatory factor 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of IRF6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386
|
|
G |
Irx1 |
iroquois homeobox 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA panobinostat results in increased expression of IRX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:31,294,615...31,300,444
|
|
G |
Irx2 |
iroquois homeobox 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA panobinostat results in increased expression of IRX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:30,660,960...30,666,378
Ensembl chr 1:30,660,960...30,666,378
|
|
G |
Irx3 |
iroquois homeobox 3 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA panobinostat results in increased expression of IRX3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Itga8 |
integrin subunit alpha 8 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ITGA8 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510
|
|
G |
Itga9 |
integrin subunit alpha 9 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of ITGA9 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:118,307,424...118,615,527
Ensembl chr 8:118,307,381...118,613,754
|
|
G |
Itgb5 |
integrin subunit beta 5 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of ITGB5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itih5 |
inter-alpha-trypsin inhibitor heavy chain 5 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA Panobinostat results in increased expression of ITIH5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207
|
|
G |
Itm2a |
integral membrane protein 2A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA panobinostat results in increased expression of ITPR2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Jade2 |
jade family PHD finger 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of JADE2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984
|
|
G |
Jarid2 |
jumonji and AT-rich interaction domain containing 2 |
increases expression |
ISO |
Panobinostat results in increased expression of JARID2 mRNA |
CTD |
PMID:33770205 |
|
NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690
|
|
G |
Jazf1 |
JAZF zinc finger 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of JAZF1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:81,881,061...82,183,100
|
|
G |
Jcad |
junctional cadherin 5 associated |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of JCAD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:53,089,382...53,130,996
Ensembl chr17:53,089,382...53,130,967
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of JDP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
panobinostat results in increased expression of JUN mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KANK4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA panobinostat results in decreased expression of KAT2B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kat6a |
lysine acetyltransferase 6A |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA |
CTD |
PMID:27188386 |
|
NCBI chr16:69,084,914...69,165,923
Ensembl chr16:69,084,914...69,163,606
|
|
G |
Kat7 |
lysine acetyltransferase 7 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA panobinostat results in decreased expression of KAT7 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr10:80,221,519...80,255,590
Ensembl chr10:80,221,524...80,255,567
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of KBTBD11 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kcna7 |
potassium voltage-gated channel subfamily A member 7 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:95,886,073...95,891,565
Ensembl chr 1:95,886,073...95,891,565
|
|
G |
Kcnc1 |
potassium voltage-gated channel subfamily C member 1 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA panobinostat results in decreased expression of KCNC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:96,902,953...96,944,744
Ensembl chr 1:96,902,953...96,944,744
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA panobinostat results in decreased expression of KCND2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KCNG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
|
|
G |
Kcnh5 |
potassium voltage-gated channel subfamily H member 5 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA panobinostat results in decreased expression of KCNH5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:93,615,174...93,908,107
Ensembl chr 6:93,624,529...93,908,107
|
|
G |
Kcnj13 |
potassium inwardly-rectifying channel, subfamily J, member 13 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA panobinostat results in decreased expression of KCNJ13 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kcnk1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA panobinostat results in decreased expression of KCNK10 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695
|
|
G |
Kcnmb4 |
potassium calcium-activated channel subfamily M regulatory beta subunit 4 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 7:52,066,145...52,119,098
Ensembl chr 7:52,066,136...52,119,278
|
|
G |
Kcnn3 |
potassium calcium-activated channel subfamily N member 3 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA panobinostat results in decreased expression of KCNN3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145
|
|
G |
Kcnv1 |
potassium voltage-gated channel modifier subfamily V member 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170
|
|
G |
Kctd1 |
potassium channel tetramerization domain containing 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA panobinostat results in increased expression of KCTD1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA panobinostat results in increased expression of KCTD12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA |
CTD |
PMID:27188386 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kiaa0040 |
KIAA0040 ortholog |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA panobinostat results in increased expression of KIAA0040 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:72,274,519...72,312,103
Ensembl chr13:72,274,552...72,312,103
|
|
G |
Kiaa1549 |
KIAA1549 homolog |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of KIAA1549 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:66,840,674...66,968,407
Ensembl chr 4:66,760,162...66,968,436
|
|
G |
Kiaa1755 |
KIAA1755 ortholog |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KIAA1755 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA1755 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:146,850,558...146,884,238
Ensembl chr 3:146,850,557...146,884,871
|
|
G |
Kif13a |
kinesin family member 13A |
decreases expression |
ISO |
panobinostat results in decreased expression of KIF13A mRNA |
CTD |
PMID:26272509 |
|
NCBI chr17:17,766,597...17,948,517
Ensembl chr17:17,766,597...17,943,615
|
|
G |
Kif28 |
kinesin family member 28 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:91,427,527...91,482,297
Ensembl chr13:91,427,736...91,482,237
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KIFAP3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650
|
|
G |
Kiss1r |
KISS1 receptor |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KIT mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kitlg |
KIT ligand |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KITLG mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kiz |
kizuna centrosomal protein |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of KIZ mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:134,277,631...134,385,260
Ensembl chr 3:134,277,687...134,385,190
|
|
G |
Klf15 |
KLF transcription factor 15 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KLF15 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KLF5 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA panobinostat results in increased expression of KLF6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl14 |
kelch-like family member 14 |
increases expression |
ISO |
panobinostat results in increased expression of KLHL14 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr18:12,804,253...12,917,828
Ensembl chr18:12,804,253...12,917,828
|
|
G |
Klk10 |
kallikrein related-peptidase 10 |
multiple interactions |
ISO |
[Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA |
CTD |
PMID:21791302 |
|
NCBI chr 1:94,234,536...94,239,369
Ensembl chr 1:94,235,096...94,239,376
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA panobinostat results in increased expression of KLK8 mRNA |
CTD |
PMID:21791302 PMID:26272509 PMID:27188386 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Klrg2 |
killer cell lectin like receptor G2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KLRG2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:67,360,216...67,374,867
Ensembl chr 4:67,363,919...67,374,147
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of KREMEN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:80,081,870...80,147,489
Ensembl chr14:80,084,403...80,147,516
|
|
G |
Krt18 |
keratin 18 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA panobinostat results in increased expression of KRT18 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Krt19 |
keratin 19 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt8 |
keratin 8 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA panobinostat results in increased expression of KRT8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA panobinostat results in increased expression of L1CAM mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G |
L1td1 |
LINE-1 type transposase domain containing 1 |
increases expression |
ISO |
panobinostat results in increased expression of L1TD1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr 5:113,373,193...113,386,088
Ensembl chr 5:113,379,870...113,385,730
|
|
G |
Lacc1 |
laccase domain containing 1 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LACC1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:52,390,267...52,407,630
Ensembl chr15:52,395,183...52,407,545
|
|
G |
Lactb |
lactamase, beta |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LACTB mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:67,571,500...67,587,539
|
|
G |
Lama2 |
laminin subunit alpha 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LAMA2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530
|
|
G |
Lama4 |
laminin subunit alpha 4 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LAMA4 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LAMC2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LAMP2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Layn |
layilin |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LAYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:51,363,928...51,384,748
Ensembl chr 8:51,367,091...51,384,330
|
|
G |
Lctl |
lactase-like |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LCTL mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:64,618,350...64,639,357
|
|
G |
Ldhd |
lactate dehydrogenase D |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LDHD mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr19:39,583,529...39,588,397
Ensembl chr19:39,573,621...39,595,575
|
|
G |
Lemd1 |
LEM domain containing 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LEMD1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr13:43,631,705...43,697,765
Ensembl chr13:43,665,926...43,697,948
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgals3 |
galectin 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LGALS3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhfpl6 |
LHFPL tetraspan subfamily member 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LHFPL6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
|
|
G |
Lhx2 |
LIM homeobox 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA panobinostat results in decreased expression of LHX2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
|
|
G |
Lhx8 |
LIM homeobox 8 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA panobinostat results in increased expression of LHX8 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:243,244,958...243,269,624
Ensembl chr 2:243,244,961...243,269,416
|
|
G |
Lifr |
LIF receptor subunit alpha |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA panobinostat results in increased expression of LIFR mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
|
|
G |
Lim2 |
lens intrinsic membrane protein 2 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 1:93,837,597...93,843,769
Ensembl chr 1:93,837,597...93,843,769
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LIMCH1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lin28b |
lin-28 homolog B |
multiple interactions affects expression decreases expression |
ISO |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein] panobinostat affects the expression of LIN28B mRNA panobinostat results in decreased expression of LIN28B protein |
CTD |
PMID:26733615 |
|
NCBI chr20:48,865,329...48,964,769
Ensembl chr20:48,869,485...48,955,077
|
|
G |
Lingo2 |
leucine rich repeat and Ig domain containing 2 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LINGO2 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:50,370,744...51,687,252
Ensembl chr 5:50,367,101...50,516,956
|
|
G |
Lix1 |
limb and CNS expressed 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LIX1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:58,128,961...58,187,554
Ensembl chr 1:58,128,961...58,185,964
|
|
G |
Lman1 |
lectin, mannose-binding, 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LMAN1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
|
|
G |
Lmf1 |
lipase maturation factor 1 |
increases expression |
ISO |
panobinostat results in increased expression of LMF1 mRNA |
CTD |
PMID:26272509 |
|
NCBI chr10:14,597,726...14,684,071
Ensembl chr10:14,597,594...14,684,119
|
|
G |
Lmo2 |
LIM domain only 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA panobinostat results in decreased expression of LMO2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:90,355,234...90,377,970
Ensembl chr 3:90,365,883...90,377,953
|
|
G |
Lmo3 |
LIM domain only 3 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LMO3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:171,234,696...171,292,222
|
|
G |
Lmo7 |
LIM domain 7 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr15:78,566,999...78,769,833
Ensembl chr15:78,567,023...78,769,783
|
|
G |
Lnx1 |
ligand of numb-protein X 1 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA panobinostat results in increased expression of LNX1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:33,514,429...33,617,086
Ensembl chr14:33,514,436...33,617,086
|
|
G |
LOC100912195 |
protein BEX1-like |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA panobinostat results in increased expression of BEX5 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 1:110,047,861...110,051,812
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LPAR6 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Lrig1 |
leucine-rich repeats and immunoglobulin-like domains 1 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LRIG1 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513
|
|
G |
Lrp12 |
LDL receptor related protein 12 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LRP12 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 7:70,941,068...71,012,409
Ensembl chr 7:70,941,068...71,012,441
|
|
G |
Lrp2 |
LDL receptor related protein 2 |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA panobinostat results in decreased expression of LRP2 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
|
|
G |
Lrp8 |
LDL receptor related protein 8 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 5:122,563,468...122,635,434
Ensembl chr 5:122,563,453...122,631,352
|
|
G |
Lrrc17 |
leucine rich repeat containing 17 |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA panobinostat results in increased expression of LRRC17 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845
|
|
G |
Lrrc3b |
leucine rich repeat containing 3B |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA panobinostat results in decreased expression of LRRC3B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr15:9,973,580...10,050,891
Ensembl chr15:9,969,983...10,051,066
|
|
G |
Lrrc55 |
leucine rich repeat containing 55 |
decreases expression multiple interactions |
ISO |
panobinostat results in decreased expression of LRRC55 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:70,269,908...70,280,651
Ensembl chr 3:70,265,936...70,278,639
|
|
G |
Lrrc8b |
leucine rich repeat containing 8 VRAC subunit B |
multiple interactions decreases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA panobinostat results in decreased expression of LRRC8B mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr14:4,350,462...4,416,336
Ensembl chr14:4,354,508...4,416,311
|
|
G |
Lrrc8e |
leucine rich repeat containing 8 VRAC subunit E |
multiple interactions increases expression |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA panobinostat results in increased expression of LRRC8E mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412
|
|
G |
Lrrfip1 |
LRR binding FLII interacting protein 1 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250
|
|
G |
Lrrn3 |
leucine rich repeat neuronal 3 |
multiple interactions affects expression increases expression |
ISO |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA] panobinostat affects the expression of LRRN3 mRNA panobinostat results in increased expression of LRRN3 mRNA |
CTD |
PMID:26272509 PMID:26733615 PMID:27188386 |
|
NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
|
|
G |
Lrrn4 |
leucine rich repeat neuronal 4 |
multiple interactions |
ISO |
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA |
CTD |
PMID:27188386 |
|
NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831
|
|
G |
LRRTM1 |
leucine rich repeat transmembrane neuronal 1 |
multiple interactions affects expression |
ISO |
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA] panobinostat affects the expression of LRRTM1 mRNA |
CTD |
PMID:26733615 PMID:27188386 |
|
NCBI chr 4:109,701,815...109,718,924
Ensembl chr 4:109,701,815...109,717,184
|
|
G |
Ly75 |
lymphocyte antigen 75 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LY75 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 3:44,764,702...44,852,219
Ensembl chr 3:44,765,122...44,852,374
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LYN mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Lypd3 |
Ly6/Plaur domain containing 3 |
increases expression multiple interactions |
ISO |
panobinostat results in increased expression of LYPD3 mRNA [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA |
CTD |
PMID:26272509 PMID:27188386 |
|
NCBI chr&nbs |